Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full...(3958 - Deferred income ta...)

Deferred income tax - long term 75 -

Deferred revenue 4,607 3,667

Deferred rent 10 128

Deferred compensation plan liabilities 1,893 1,211

Commitments and contingencies

Stockholders' equity:

Preferred stock, $.0001 par value per share,

20,000,000 shares authorized,

none issued and outstanding - -

Common stock, $.0001 par value per share;

200,000,000 shares authorized,

53,916,298 and 52,233,656 shares issued and

outstanding at December 31, 2007 and

December 31, 2006, respectively 5 5

Additional paid-in capital 415,229 334,184

Accumulated other comprehensive income (loss) 1,604 (5)

Retained earnings 321,202 236,024

Total stockholders' equity 738,040 570,208

Total liabilities and stockholders' equity $789,053 $623,839

Gen-Probe Incorporated

Consolidated Statements of Income

(In thousands, except per share data)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Revenues:

Product sales $92,426 $85,496 $370,877 $325,307

Collaborative research revenue 5,380 1,194 16,619 15,937

Royalty and license revenue 1,143 4,369 15,518 13,520

Total revenues 98,949 91,059 403,014 354,764

Operating expenses:

Cost of product s
'/>"/>